At a glance
- Originator Chugai Pharmaceutical
- Class Uricosurics
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Gout
Most Recent Events
- 15 Nov 2006 Discontinued for Gout in Japan (PO)
- 08 Sep 2000 No-Development-Reported for Gout in Japan (PO)